The data indicate that many HCC models respond to LXRα agonist and TGFβ stimulation; in certain HCCs, TGFβ partially antagonizes the stimulatory effect of T0901317 on FASN expression and LXRα stabilization. Here, NR1H3 is linked to hepatocellular carcinoma.